Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (parietal cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: netazepide, ci-988, itriglumide +1 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 261 | 0.91 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 9221
Sealed predictions
- CCKBR in dopamine neurons, braak-0.32 (p 0.402) → +0.05 (p 0.892)receipt 9228
Swarm cases
receipt 9228: CCKBR in dopamine neurons, braak
- power
- full sample -0.13 (p 0.597, n 18), 95% CI -0.57 to +0.36. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.12 (p 0.627, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range -0.27 to -0.03, sign flips 0; without severely affected donors -0.13 (p 0.597, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCKBR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts